Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly-Reference-Cited by-同舟云学术

Discovery and SAR Studies of Orally Active Somatostatin Receptor Subtype-2 (SSTR2) Agonists for the Treatment of Acromegaly

Published:2020-04-21 Issue:10 Volume:11 Page:1482-1494
ISSN:1948-7193
Container-title:ACS Chemical Neuroscience
language:en
Short-container-title:ACS Chem. Neurosci.

Author:

Ishida Akiharu¹^ORCID,Tajima Yohei¹,Okabe Yasuyuki¹,Matsushita Takeshi¹,Sekiguchi Tetsuya¹,Imaide Satomi¹,Nomura Yoshinori¹,Tanaka Motoyuki¹,Nojima Shoji¹,Yoshida Atsushi¹,Iyoda Yoko¹,Aoki Shohei¹,Nishio Takuya²,Komagata Tatsuya²,Iwaki Masanori²,Shono Tomoyuki³,Naganawa Atsushi¹,Imagawa Akira¹

Affiliation:

1. Medicinal Chemistry Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto, Mishima-gun, Osaka 618-8585, Japan

2. Department of Biology & Pharmacology, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

3. Pharmacokinetic Research Laboratories, Ono Pharmaceutical Co., Ltd, 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan

Publisher

American Chemical Society (ACS)

Subject

Cell Biology,Cognitive Neuroscience,Physiology,Biochemistry,General Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acschemneuro.0c00124

Reference13 articles.

1. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review